Inhaled Epinephrine

Phase 1Small molecule

DDr. George Luciuk

Inhaled Epinephrine is one of 2 small molecule programs targeting Hypersensitivity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypersensitivityRecruiting

HypersensitivityPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Hypersensitivity

#DrugCompanyPhaseTrials

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 2

Inhaled Epinephrine

DDr. George Luciuk

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hypersensitivity

NCT07038746

Clinical

Trials by Indication[1]

Allergy1 trial

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

Completed·—·Phase 1·NCT06445374·21 enrolled

Hypersensitivity1 trial

A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

Recruiting·DDr. George Luciuk·Phase 1·NCT07038746·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Inhaled Epinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled Epinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled Epinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. George Luciuk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDr. George Luciuk

Inhaled Epinephrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Allergy1 trial

Hypersensitivity1 trial

References

Drug Info

Quick Facts

Related News